Validive, an agonist of alpha-2 adrenergic receptors, is designed to deliver high concentrations of the active principle (clonidine) locally in the oral cavity, the site of damage during radiotherapy of head and neck cancer that leads to severe oral mucositis (SOM). Clonidine reduces the expression of cytokines, the molecules that are responsible for the ulcerations and pain in SOM, by white blood cells in the oral mucosa. The MBT technology delivers high salivary concentrations of clonidine and minimizes systemic absorption allowing for maximal local dosing of drug to the at risk oral mucosa. A randomized, double-blinded phase II trial confirmed Validive’s mechanism of action and demonstrated:
Learn more about Severe oral mucositis (SOM).